Defining the molecular pathology and consequent phenotypes in Egyptian HB patients

Ghada Y. El-Kamah 1, Rehab M. Mosaad 2*, Mohamed B. Taher 1 and Khalda S. Amr 3

Abstract

Background: Hemophilia B (HB) (also known as Christmas disease) is a rare X-linked recessive disorder characterized by spontaneous or prolonged hemorrhages caused by mutations in Factor 9 (F9) gene leading to deficient or defective coagulation F9. Our study aimed at identifying the causative mutations within a sample of HB Egyptian patients. The present study comprised clinical data of eleven HB patients descending from six unrelated families and a seventh family including a carrier mother with a history of deceased HB sibling. Sequencing of F9 gene was performed.

Results: The study revealed four mutations; two missense NM_000133.3:c.676C>G, (P.Arg226Gly) and NM_000133.3:c.1305T>G, (p.Cys435Trp), and two nonsense mutations NM_000133.3:c.880C>T, (p.Arg294*) and NM_000133.3:c.1150C>T, (p.Arg384*), identified mutations spanned exons 6 and 8 of which a total of three mutations are located in hotspot exon 8 of F9 gene.

Conclusions: Reviewing the literature, this is the first molecular analysis of F9 gene in HB Egyptian patients. Consistent genotype/phenotypic severity correlation could be concluded, helping proper genetic counseling and prenatal decision taking.

Keywords: Hemophilia B, Factor IX gene, Nonsense mutations, Sequencing

Background

Hemophilia-B (HB, OMIM 306900) is the second most common form of hemophilia after hemophilia-A accounting for 15-20% of hemophilia affection. HB incidence is estimated as one in 30,000 live male births worldwide with rare reports of affected females [1]. However, reports vary widely, and the prevalence of hemophilia B per 100,000 males in 103 countries ranged from 0.01 (Nigeria) to 8.07 (Ireland). In 2019, the World Federation of Hemophilia (WFH), in its global survey in Egyptian population (98,423,595) estimated the number of affected patients with hemophilia as 6028 [2].

Based on the plasma levels of F9, HB patients are clinically classified as severe (<1%), moderate (1-5%), and mild (5-40%). Severely affected males suffer from frequent spontaneous bleeding mainly in joints and muscles while mild or moderate cases experience excessive bleeding only upon trauma [3].

Hemophilia-B is caused by a wide variety of heterogeneous and infrequent mutations in F9 gene. The F9 gene (OMIM 300746) located on the Xq27.1 is 34 kb in length encompassing 8 exons encoding 2.8 kb mRNA. Full length F9 gene contains 451 amino acid residues and includes a signal peptide (1-28 residues), a propertied (29-46) domain Gla enriched with glutamate (47-92), two EGF-like domain EGF1 (93-129) and EGF2 (130-171), a linker (172-191), an activation peptide (192-226), and SP domain of serine protease (227-451) [4, 5].

Underlying F9 gene mutations is responsible for the phenotypic severity and bleeding tendency. A wide spectrum of F9 gene mutations causing HB has been identified in all regions of the gene. The most common...
mutation type is point mutations which account for about 73%, followed by deletion mutations 16.3%, and, in minor proportion; insertions, duplications, small indels, and large rearrangements. More than 3940 unique mutations have been reported so far in HGMD [6]. Most mutations within F9 gene can be detected by direct DNA sequencing; however, for large gross deletions, the multiple ligation—dependent probe amplification (MLPA) assay could be employed [1].

This study aims at the identification of pathogenic mutations verified by gene screening and describing the clinical outcomes from variants identified in a sample of Egyptian HB patients referred to the Hereditary Blood Disorders clinic, (NRC) Egypt, and develop a first step in building knowledge about the molecular basis of this disease in Egyptian patients ultimately helping to provide proper genetic counseling.

Methods
The Institutional Review Board NRC according to the World Medical Association Declaration of Helsinki approved the current research. Eleven HB male patients descending from six unrelated pedigrees and a seventh family including a carrier mother with a history of deceased HB patient were recruited from the Hereditary Blood Disorders clinic, NRC. Patients’ ages ranged from 1 to 20 years old and their ages at disease onset ranged from 22 days-3 years. They were all descending from non-consanguineous families. Patients were included based on the presence of a history of bleeding and laboratory findings including prolonged activated partial thromboplastin time (aPTT), normal thromboplastin time (PT), and deficient F9. Patients were subjected to detailed medical history recording including three-generation pedigree analyses, demographic data, initial complaint, age at onset, history of present illness, and disease progression, coupled with thorough clinical evaluation with emphasis on hemarthrosis. Patients were then phenotypically classified according to bleeding episodes and the level of F9 activity into one mild (>5%) and two moderate (1–5%) HB patients with history of severe bleeding following trauma, and eight severe (<1%) HB patients presenting with history of spontaneous joints and/or muscles bleeding episodes. Written informed consents were obtained from all participants and/or legal guardians. Peripheral blood samples (3 ml) were collected in EDTA tubes from all recruited patients and their available family members for genomic DNA extraction.

Mutation analysis
Genomic DNA was extracted from 2 ml peripheral blood of affected HB patients and their available family members using “DNA Mini kit Quiagen” following the manufacturer’s instructions and quantification of the isolated DNA was performed by spectrometry in a “Nanodrop 2000.”

Eight exons of F9 gene were amplified by polymerase chain reaction (PCR) of primers designed by ExonPrimer SOFTWARE. The coding regions and exon/intron boundaries of approximately 50 bp sequence were investigated to recognize any splice site variants as well. The PCR products were purified using Exo-SAP PCR purification kit (Fermentas, Germany) and both directions were sequenced using BigDye Terminator v3.1 Cycle Sequencing Kit and analyzed on the ABI Prism 3500 Genetic Analyzer (Applied Biosystems) according to manufacturer’s instructions.

The sequence data of F9 gene was compared with reference genomic and cDNA sequence of the gene nucleotide numbering based on the Genebank accession numbers IX (F9), RefSeqGen LRG 556 on chromosome X, NM_000133.3 and NP_000124.1, with c.1 denoting the first position of the translation start codon obtained from National Center for Biotechnology Information (NCBI) database. Mutation nomenclature was given according to Genetic Variations approved by the Human Genome Variation Society (HGVS) (http://www.hgvs.org). Results were examined using Ensembl genome browser (https://www.ensembl.org/index.html).

To ascertain whether a variant was novel or not, all of the mutations in this study were compared to the international F9 gene databases (http://www.factorix.org; https://www.cdc.gov/ncbddd/hemophilia/champs; http://www.hemobase.com/).

Results
In this study, eleven HB male patients descending from six unrelated pedigrees were investigated. Patients’ ages ranged from 1 to 20 years old and their ages at disease onset ranged from 22 days-3 years. They were all descending from non-consanguineous families residing in different governorates in Egypt. According to F9 activity, eight HB cases were phenotypically classified as severe, two as moderate, and one mild. Family 7 presented with a history of previous death of HB sibling with severe phenotype.

Mutational analysis of the coding region of the F9 gene identified biallelic pathogenic mutations in all our HB patients (Table 1). Two HB patients 1 and 2 harbored homozygous missense mutation, namely (NM_000133.3: c.676C>G; NP_000124.1: p. Arg226Gly) located in exon six (Fig. 1a).

HB patient 3 demonstrated another homozygous missense mutation (NM_000133.3:c.1305T>G, NP_000124.1: p.Cys435Trp) which is located in exon eight (Fig. 1b). One stop codon homozygous nonsense mutations located in exon 8 was characterized in cases
and their affected family members within families no. 4, 5, and 6: (NM_000133.3:c.880C>T, NP_000124.1: p.Arg294*) (Fig. 1c). Another nonsense mutation presenting in a heterozygous state (NM_000133.3: c.1150C>T, NP_000124.1:p.Arg384*) was identified in exon 8 in carrier mother of Family 7 (Fig. 1d). All identified causative mutations within \textit{F9} gene have been reported previously in \textit{F9} Mutation Database sites and Human Genome Mutation Database HGMD [6] (Fig. 2).

### Table 1
Characterization of the variants identified in the families with HB

| Patients ID | Nucleotide change | Location | Amino acid change | Mutation effect | Severity | Domain | Citation |
|-------------|-------------------|----------|-------------------|-----------------|----------|--------|---------|
| HB-1        | c.676 C>G         | Exon 6   | p.Arg226Gly       | Missense        | Moderate | Activation peptide | 6       |
| HB-2        | c.676 C>G         | Exon 6   | p.Arg226Gly       | Missense        | Moderate | Activation peptide | 6       |
| HB-3        | c.1305 T>G        | Exon 8   | p.Cys435Tyr       | Missense        | Mild     | Serine protease    | 2       |
| HB-4        | c.880 C>T         | Exon 8   | p. Arg294*        | Nonsense        | Severe   | Serine protease    | 70      |
| HB-4.1      | c.880 C>T         | Exon 8   | p. Arg294*        | Nonsense        | Severe   | Serine protease    | 70      |
| HB-4.2      | c.880 C>T         | Exon 8   | p. Arg294*        | Nonsense        | Severe   | Serine protease    | 70      |
| HB-4.3      | c.880 C>T         | Exon 8   | p. Arg294*        | Nonsense        | Severe   | Serine protease    | 70      |
| HB-5        | c.880 C>T         | Exon 8   | p. Arg294*        | Nonsense        | Severe   | Serine protease    | 70      |
| HB-5.1      | c.880 C>T         | Exon 8   | p. Arg294*        | Nonsense        | Severe   | Serine protease    | 70      |
| HB-5.2      | c.880 C>T         | Exon 8   | p. Arg294*        | Nonsense        | Severe   | Serine protease    | 70      |
| HB-6        | c.880 C>T         | Exon 8   | p. Arg294*        | Nonsense        | Severe   | Serine protease    | 70      |
| Carrier mother-7 | c.1150 C>T | Exon 8 | p. Arg384*        | Nonsense | NA       | Serine protease    | 5       |

NA: not available

### Discussion
Reviewing the literature, this is the first molecular HB study in Egypt. The pathogenic variants for HB were successfully identified in all studied patients; mutations were homozygous in patients and heterozygous in carrier mothers as per the X-linked recessive inheritance mode of the disease.

Mutational screening of \textit{F9} gene in eleven clinically diagnosed Egyptian hemophilia-B patients and carrier mothers revealed four point mutations including two
missense and two nonsense mutations that were correlating with phenotypic severity within the studied patients. Up to November 2018, the F9 gene mutation database (EAHD Coagulation Factor Variant Databases) has recorded a total of 1094 mutations in 3713 HB patients [7], more than 3940 unique mutations have been reported so far in HGMD, 2020 [6]; point mutations accounts for 73.1% and mutations within the serine protease domain (SPD) account for about 56.1% among different populations [5, 8–17]. In agreement with that, all the detected mutations within our studied cohort were point mutations, three out of four detected mutations are within the protease domain, the greater part of codons (280–451) coded by the largest exon in the F9 gene (exon 8).

Our patients presented with the classical phenotypic characteristics of the HB disease including severely affected males suffering from frequent spontaneous bleeding mainly in joints and muscles while boys with mild or moderate HB disease excessive bleeding only upon trauma.

We identified one missense mutation (NM_000133.3: c.676C>G; NP_000124.1: p.Arg226Gly) located in exon 6 in two HB patients (patients 1 and 2) who clinically presented with moderate phenotype. However, severe and moderate forms of the disease resulting from this mutation have been reported earlier in different populations like China, Turkey, and France [18–20]; this might be attributed to different ethnic backgrounds [5–21].

The missense mutation c.676C>G where cytosine was substituted to guanine at nucleotide 676 results in the replacement of positively polar arginine with uncharged polar amino acid glycine at codon 226 in activation peptide domain causing an alteration in its structure and decreased protein function, since arginine residues are known to be involved in the formation of salt bridges and hydrogen bonds [22].

Another identified missense mutation (NM_000133.3: c.1305T>G, NP_000124.1: p.Cys435Trp) was detected in one patient (patient 3) who presented with a mild phenotype. This mutation was previously reported in two Tunisian patients presenting with both severe and mild forms of the disease [21]. According to Elmahmoudi et al. 2012 [21], the discrepancy may be explained by the intervention of other hemostatic factors, which can modify the clinical severity of hemophilia. The corresponding mutation in codon 435 is located in the junction regions between the activation domain and its adjacent domains suggesting that the mutation might interfere with the normal cleavage process and resulting in the production of partially dysfunctional FIX proteins which might explain its association with the milder phenotype in our patient [5].

Interestingly, there are seventy patients’ data available in the Factor IX Variant database reporting the detected nonsense mutation (NM_000133.3:c.880C>T, NP_000124.1:p.Arg294*) in exon 8, leading mostly to moderate and severe forms of the disease in patients from different ethnic backgrounds. In the current study, the severe form of the disease was observed in three studied patients (patients 4, 5, and 6) and their affected families members where factor IX activity was <1% [5, 18, 23–26].

The seventh family (7) was seeking pre-conception counseling for a history of a deceased HB child. DNA from the carrier mother was sequenced and the causative mutation was characterized as a nonsense mutation (NM_000133.3:c.1150C>T, NP_000124.1:p.Arg384*) in exon 8 of the F9 gene which was previously reported in Colombian, Brazilian, and Argentinian populations with moderate and severe forms of the disease [23, 27, 28]. The data obtained from this study will be used for carrier testing and prenatal diagnosis when requested.

The two nonsense mutations (p.Arg294*, p.Arg384*) were detected in eight patients descending from four unrelated HB families (families 4, 5, 6, 7) who presented with the severe phenotype, were previously described in patients bearing moderate and severe forms of the disease.
Our results are in agreement with the conclusion of Belvini et al. 2005 [26] who stated that the nonsense mutations are expected to produce truncated unstable proteins as a result of premature translation or the involvement of the Nonsense-Mediated mRNA Decay (NMD) system regardless of their location.

In addition, these two mutations (p.Arg294*, p.Arg384*) present in the serine protease domain; the greater part of which (codons 280–451) is coded by the largest exon in the F9 gene (exon 8), where CpG dinucleotides are considered to be mutation hot spots that are the highly susceptible site for mutation within the F9 gene [24–29].

Currently, the multiplex ligation dependent probe amplification (MLPA) method is used to detect large deletion or duplication mutations in F9 gene, however, it cannot detect point mutations that are considered as the major type of causative mutations in HB [8], and our studied patients were all diagnosed through direct sequencing of all coding exons of the F9 gene.

Conclusion
We could successfully define the mutational spectrum of F9 gene in our cohort of eleven Egyptian HB patients descending from 6 unrelated pedigrees and one carrier female from a seventh family. A total of four different mutations were identified, which further confirms the high degree of heterogeneity in the mutations within F9 gene. Mutation detection allows proper genetic counseling, carrier detection of female relatives, and prenatal genetic services.

Further studies with larger patients’ numbers are highly recommended to build an Egyptian database and confirm the genotype–phenotype correlation within our ethnic background. In absence of definitive curative treatment of hemophilia B disease, which results in most instances in patients’ mortality and/or disability, this database could help in trials for modern therapeutic possibilities where the molecular background has to be defined such as the evolving gene-editing technology.

Acknowledgements
Not applicable

Authors’ contributions
Ghada El-Kamah (GYK), Khalda Amr (KSA), Rehab Mosaad (RMW), Mohamed Taher (MBT). GYK and MBT: clinical evaluation and case selection, RMW: nucleic acid extraction and sequencing analysis, KSA: supervision of experimental work, RMW and KSA: molecular verification and in silico analysis, RMW and MBT: preparation of manuscript first draft, GYK and KSA: editing of manuscript in its different versions and final revision. All authors read and approved the final manuscript.

Funding
Not applicable

Availability of data and materials
All data generated or analyzed during this study are included in this article.

Declarations
Ethics approval and consent to participate
Written informed consents were obtained from all participants and/or legal guardians.

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Author details
1Clinical Genetics Department, Human Genetics and Genome Research division (HGGR), National Research Centre (NRC), Cairo, Egypt. 2Molecular Genetics and Enzymology Department, HGGR, NRC, El Buhouth St, Dokki, Cairo, Egypt. 3Medical Molecular Genetics, HGGR, NRC, Cairo, Egypt.

Received: 29 January 2021 Accepted: 14 April 2021
Published online: 17 May 2021

References
1. Lin XY, Wang J, Xiao X, Xu YW, Yan QJ, Jiang WY (2018) Establishing a comprehensive genetic diagnosis strategy for hemophilia B and its application in Chinese population. Int J Lab Hematol 40(2):215–228. https://doi.org/10.1111/ijlh.12771
2. World Federation of Hemophilia report on the Annual Global Survey (2019). http://www1.wfh.org/publications/files/pdf-1627.pdf. Accessed 7 July 2019
3. Xie X, Chen C, Liang Q, Wang X, Wu X, Wang W, Ding Q (2019) Characterization of two large duplications of F9 associated with mild and severe haemophilia B, respectively. Haemophilia 25(3):475–483. https://doi.org/10.1111/hae.13704
4. Rogers AE, Bowman JD, Weineren J, Monsalve R, Mozdzen T (2015) Radiometric measurements of electron temperature and opacity of ionospheric perturbations. Radio Sci 50(2):130–137. https://doi.org/10.1002/2014RS005399
5. Rallapalli PM, Kemball-Cook G, Tuddenham EG, Gomez K, Perkins SJ (2013) An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B. J Thromb Haemost 11(7):1329–1340. https://doi.org/10.1111/jth.12276
6. Human gene mutation database (2020). http://www.hgmd.cf.ac.uk/ac/index.php. Accessed 20 Dec 2020
7. EAHD (2018) Coagulation factor variant databases http://www.factorix.org/statslist.shtml
8. Lv XM, Li TM, Li HM, Liu H, Wang ZM, Guo Z (2019) Genetic analysis of a hemophilia B family with a novel F9 gene mutation. Medicine 98(21): e15688. https://doi.org/10.1097/MD.0000000000015688
9. Lu Y, Wu X, Dai J, Ding Q, Wu W, Wang X (2019) The characteristics and spectrum of F9 mutations in Chinese sporadic haemophilia B pedigrees. Haemophilia 25(2):316–323. https://doi.org/10.1111/hae.13681. Epub 2019 Jan 16
10. Surin EV, Demidova OS, Selivanova YA, Luchrina WJ, Salomakhina OS, Pshenichnikova EA, Likhacheva (2016) Mutational analysis of hemophilia B in Russia: Molecular-genetic study. Russian Journal of Genetics 52, 409–415. https://doi.org/10.1134/S1022795416040116
11. Li T, Miller CH, Driggers J, Payne AB, Ellingsen D, Hooper WC (2014) Mutation analysis of a cohort of US patients with hemophilia B. Am J Hematol 89(4):375–379. https://doi.org/10.1002/ajh.23645
12. Pei-Chen L, Yi-Ning S, Yu-Mei L, Tai-Tsong C, Shi-Hen P, Hsu-Lan S, Shyh-Shin C (2014) Efficient detection of factor IX mutations by denaturing high-performance liquid chromatography in Taiwanese hemophilia B patients, and the identification of two novel mutations. Kaohsiung J Med Sci 30:187–193
13. Li T, Miller CH, Payne AB et al (2013) The CDC hemophilia B mutation project mutation list; a new online resource. Mol Genet Genomic Med. https://doi.org/10.1002/mgg3.130
14. Radic CP, Rossetti LC, Abellayro MM, Candela M, Pérez Bianco R, de Tezanos Pinto M, Laripa IB, Goodeve A, de Brasi C (2013) Assessment of the F9 genotype-specific FIX inhibitor risks and characterisation of 10 novel severe F9 defects in the first molecular series of Argentinian patients with...
haemophilia B. Thromb Haemost 109(1):24–33. https://doi.org/10.1160/TH12-05-0302
15. Morteza K, Sirous Z, Edward GT, Nafiseh N, Manijeh L, Peter G (2009) Molecular characterization of the factor IX gene in 28 Iranian hemophilia B patients. Iran J Blood Cancer 2:43–47
16. Nazia N, Rashid H, Khalid M, Najib G (2008) Molecular basis of hemophilia B in Pakistan: identification of two novel mutations. World J Med Sci 3(2):50–53
17. Morteza K, Sirous Z, Nafiseh N, Edward GD, Manijeh L, Reza S (2007) Identification of factor IX mutations in Iranian haemophilia B patients by SSCP and sequencing. Thromb Res 120:135–139
18. Yu T, Dai J, Liu H, Ding Q, Lu Y, Wang H, Wang X, Fu Q (2012) Spectrum of F9 mutations in Chinese hemophilia B patients: identification of 20 novel mutations. Pathology 44(4):342–347 ISBN 0031-3025. https://doi.org/10.1097/PAT.0b013e3283443d
19. Onay UV, Kavakli K, Kilinc Y (2003) Molecular pathology of haemophilia B in Turkish patients: identification of a large deletion and 33 independent point mutations. Br J Haematol 120(4):656–659. https://doi.org/10.1046/j.1365-2141.2003.04141.x
20. Ghanim N, Costes B, Martin J et al (1993) Twenty-four novel hemophilia B mutations revealed by rapid scanning of the whole factor IX gene in a French population sample. Eur J Hum Genet 1(2):144–155. https://doi.org/10.1159/000472401
21. Elmahmoudi H, Belhedi N, Ilizi A, Zahra K, Meddeb B, Elgaaied ABA, Gouider E (2011) Factor VIII haplotypes frequencies in Tunisian hemophilic a. Diagn Pathol 6(1):54. https://doi.org/10.1186/1746-1596-6-54
22. Donald JE, Kulp DW, DeGrado WF (2011) Salt bridges: geometrically specific, designable interactions. Proteins 79(3):898–915. https://doi.org/10.1002/prot.22927
23. Jara P, Hazbun Y, Linares A, Londoño Y (2020) Molecular characterization of hemophilia B patients in Colombia. Mol Genet Genomic Med 8(1):e1210
24. Abla Z, Mouloud Y, El H, Emna G, Abdi Meriem A, Ouarhlent Yamina O, Naouel S (2018) Mutations causing hemophilia B in Algeria: identification of two novel mutations of the factor 9 gene. Biodiversitas 19(1):52–58. https://doi.org/10.13057/biodiv/d190109
25. Khan MT, Naz A, Ahmed J, Shamsi T, ty AJS (2018) Mutation spectrum and genotype – phenotype analyses in a Pakistani cohort with hemophilia B. Clin Appl Thromb Hemost 24(4):741–748. https://doi.org/10.1177/1076029617721011
26. Belvini D, Salvioni R, Radossi P, Pierobon F, Mori P, Castaldo G, Tagariello G, AICE HB Study Group (2005) Molecular genotyping of the Italian cohort of patients with hemophilia B. Haematologica 90(5):635–642
27. Meireles MR, Pantoja AG, Omaghi AP, Vieira GF, Salzano FM, Bandinelli E (2017) Molecular characterization of hemophilia B patients in southern Brazil. Haemophilia 5:457–461. https://doi.org/10.1111/hae.1327
28. Radic CP (2010) Genética molecular de hemofilia: caracterización de mutaciones en hemofilia B, expresión de hemofilia en mujeres y desarrollo de nuevos métodos de análisis de inversiones Tesis Doctoral, Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Retrieved from http://hdl.handle.net/20.500.12110/tesis_n4794_Radic
29. Chen SH, Thompson AR, Zhang M, Scott CR (1989) Three point mutations in the factor IX genes of five hemophilia B patients. Identification strategy using localization by altered epitopes in their hemophilic proteins. J Clin Invest 84(1):113–118. https://doi.org/10.1172/JCI114130

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.